Clearmind Medicine (CMND) Free Cash Flow (2022 - 2026)

Clearmind Medicine (CMND) has reported Free Cash Flow for 5 consecutive years, with -$1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow fell 60.97% year-over-year to -$1.8 million; the trailing twelve-month figure through Apr 2026 stood at -$6.2 million (down 36.25% YoY), and the FY2025 full-year result was -$4.7 million, up 2.56% from the prior year.
• Free Cash Flow improved to -$1.8 million in Q2 2026 per CMND's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$205889.0 in Q4 2022 and bottomed at -$3053.1 billion in Q1 2023.
• Historically, Free Cash Flow has averaged -$179.6 billion across 5 years, with a median of -$1.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow plunged 216259938.4% in 2023, then soared 100.0% in 2024.
• Over 5 years, Free Cash Flow stood at -$205889.0 in 2022, then sank by 265.81% to -$753168.0 in 2023, then slumped by 43.02% to -$1.1 million in 2024, then decreased by 19.37% to -$1.3 million in 2025, then sank by 37.51% to -$1.8 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$1.8 million, -$2.1 million, and -$1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.